Ares Financial Consulting’s BridgeBio Pharma BBIO Stock Holding History

Ares Financial Consulting’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.8K	Buy	+51	New	+$3.57K	﹤0.01%	779

Other funds holding BBIO

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

MMA

Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Ares Financial Consulting's BBIO Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 51 shares worth $3.8K. The stake represents ﹤0.01% of the portfolio and ranks #779 among its holdings.

169 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Ares Financial Consulting held 51 shares of BridgeBio Pharma worth $3.8K as of Q2 2026.
BridgeBio Pharma was a new Ares Financial Consulting position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #779 holding.
169 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.